Improve walking via robotic exoskeleton
- Trial ID
- NCT06225830
- Official Title
- Utilization of Robotic EksoSkeleton to Achieve High Dosing, Intensity, and Complexity of Gait in Treatment of People With Parkinson's Disease
- Goal
- Improve walking via robotic exoskeleton
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Albert Einstein Healthcare Network
- Study Type
- INTERVENTIONAL
- Enrollment
- 24 participants
- Conditions
- Parkinson Disease
- Interventions
- Eksobionics Eksoskeleton NR
Plain-Language Summary
The goal is to improve walking and balance by giving people with Parkinson's much more high-intensity, complex gait practice than they can do safely on their own. The approach uses the Ekso wearable robotic exoskeleton to support and assist hip and leg movements so you can stand and take many more steps at a hard effort, helping retrain walking circuits and build endurance; sessions are 45 to 60 minutes with about 30 minutes at RPE 14 to 17, and the therapy is meant to complement your usual Parkinson's medications. They are enrolling adults over 18 with a physician diagnosis of idiopathic Parkinson's who report walking or balance problems, can tolerate at least 15 minutes upright and use a front-wheeled walker, and who fit device limits (under 220 pounds, roughly 5'0" to 6'4"), while people with major cognitive, neurological, cardiovascular, or musculoskeletal issues that make exoskeleton use unsafe are excluded.
Locations
- Jefferson Moss-Magee Rehabilitation - Elkins Park, Elkins Park, Pennsylvania, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Eksobionics Eksoskeleton NR. The goal is to improve walking and balance by giving people with Parkinson's much more high-intensity, complex gait practice than they can do safely on their own. The approach uses the Ekso wearable robotic exoskeleton to support and assist hip and leg movements so you can stand and take many more steps at a hard effort, helping retrain walking circuits and build endurance; sessions are 45 to 60 minutes with about 30 minutes at RPE 14 to 17, and the therapy is meant to complement your usual Parkinson's medications. They are enrolling adults over 18 with a physician diagnosis of idiopathic Parkinson's who report walking or balance problems, can tolerate at least 15 minutes upright and use a front-wheeled walker, and who fit device limits (under 220 pounds, roughly 5'0" to 6'4"), while people with major cognitive, neurological, cardiovascular, or musculoskeletal issues that make exoskeleton use unsafe are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years.